By Sam Boughedda
Investing.com — Bolt biotherapy (NASDAQ :) Stock prices have fallen after mediocre interim data from early trials of the company’s leading immunostimulatory antibody complex, the drug.
Data on a drug called BDC-1001 were shared at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) conference.
Bolt shares have fallen by more than 50.6% in the afternoon trading.
The company reported data from 57 subjects in a study spanning 16 HER2-expressing solid tumors. Her-2 is described by cancer.org as “a protein that helps the rapid growth of breast cancer cells.”
According to the company, BDC-1001 showed good safety and tolerability, showing early signs of clinical activity. In addition, early signs of clinical activity were seen in 13 of the 40 tumor-evaluable subjects.
“Bolt Biotherapeutics is committed to data-driven agile clinical development. This Phase 1/2 trial of BDC-1001 is a new candidate to mobilize the patient’s immune system to target tumors and their microenvironments. We have gained tremendous insight into our capabilities, “said Edith Perez, Bolt’s Chief Health Officer.
Fusion media Alternatively, anyone involved with Fusion Media will not be liable for any loss or damage resulting from reliance on the data, quotes, charts, trading signals and other information contained on this website. Be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.
Half of Bolt Biotherapy Strains with Mediocre Test Data from Investing.com
Source link Half of Bolt Biotherapy Strains with Mediocre Test Data from Investing.com